Real-world outcomes at 3 years follow-up of olaparib first line maintenance treatment in patients with BRCA-mutated advanced ovarian cancer: results from the United Kingdom

International Journal of Gynecological Cancer 2026

View at publisher

Authors: Rowan E. Miller, Rosalind Margaret Glasspool, Gordon C. Jayson, Juan Carlos Lopez-Baez, Betina T. Blak, Charlie Gourley

DOI: 10.1016/j.ijgc.2025.103855

Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy BRCA gene mutations in cancer Ovarian cancer diagnosis and treatment